| 摘要 |
The invention relates to compounds of formula (I), wherein A is an optionally substituted ring system, provided that the -CH(R<3>)N(R<2>)B-R<1> and -OR<4> groups are positioned in a 1,2 relationship to one another on ring carbon atoms and the ring atom positioned ortho to the OR<4> linking group (and therefore in the 3-position relative to the -CHR<3>NR<2-> linking group) is not substituted; B is an optionally substituted ring system: R<1> is positioned on ring B in a 1,3 or 1,4 relationship with the -CH(R<3>)N(R<2>)- linking group and is as defined in the specification. R<2> is hydrogen, C1-6alkyl, optionally substituted by hydroxy, cyano or trifluoromethyl, C2-6alkenyl (provided the double bond is not in the 1-position), C2-6alkynyl (provided the triple bond is not in the 1-position), phenylC1-3alkyl or pyridylC1-3alkyl; R<3> is hydrogen, methyl or ethyl; R<4> is optionally substituted: C1-6alkyl, C3-7cycloalkylC1-3alkyl or C3-7cycloalkyl; and N-oxides of -NR<2> where chemically possible; and S-oxides of sulphur containing rings where chemically possible; and pharmaceutically acceptable salts and in vivo hydrolysable esters and amides thereof. Processes for their preparation, their use as therapeutic agents and pharmaceutical compositions containing them. |
